Statin use and female reproductive organ cancer risk in a large population-based setting

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Cancer Causes and Control

• Publication date

  2009-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10552-008-9271-1PMID 19043788PMCID PMC3041638
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Applied Survival Analysis: Regression Modeling of Time-to-Event Data

  2008cited by this paper
• Statin use and prostate cancer risk in a large population-based setting

  2008cited by this paper
• Screening statins for possible carcinogenic risk: up to 9 years of follow‐up of 361 859 recipients

  2008cited by this paper
• Statin Use and Breast Cancer Risk in a Large Population-Based Setting

  2007cited by this paper
• Statins and cancer.

  2007influential reference
• Statin Use and the Risk of 10 Cancers

  2007cited by this paper
• Cancer risk among statin users: A population‐based cohort study

  2005cited by this paper
• Statins and Cancer Development

  2005cited by this paper
• Evaluating Organized Breast Cancer Screening Implementation: The Prevention of Late-Stage Disease?

  2004cited by this paper
• Statin use and cancer risk in the General Practice Research Database

  2004cited by this paper
• Evaluating Organized Breast Cancer Screening Implementation

  2004cited by this paper
• A Population‐Based Osteoporosis Screening Program: Who Does Not Participate, and What Are the Consequences?

  2004cited by this paper
• Impact of Healthcare Delivery System on Where HMO-Enrolled Seniors Purchase Medications

  2004cited by this paper
• The statins as anticancer agents.

  2003cited by this paper
• HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis

  2002cited by this paper
• Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.

  2002cited by this paper
• The Elements of Statistical Learning: Data Mining, Inference, and Prediction

  2001cited by this paper
• 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study.

  2000cited by this paper
• The use of automated data to identify complications and comorbidities of diabetes: a validation study.

  1999cited by this paper
• Carcinogenicity of lipid-lowering drugs.

  1996cited by this paper
• Carcinogenicity of lipid-lowering drugs.

  1996cited by this paper
• The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

  1996cited by this paper
• Risk factors, epidemiology, screening, and prognostic factors in female genital cancer.

  1992cited by this paper
• Revisions in the risk‐based breast cancer screening program at group health cooperative

  1990influential reference
• Drug facts and comparisons

  1977cited by this paper

• Cholesterol desensitizes the response of endometrial cancer to progestin by attenuating progestin signaling.

  2025cites this paper
• Causal relationship between lipid-lowering drugs and ovarian cancer, cervical cancer: a drug target mendelian randomization study

  2024cites this paper
• Advances in ovarian cancer treatment using a combination of statins with other drugs

  2023cites this paper
• Statins as Repurposed Drugs in Gynecological Cancer: A Review

  2022cites this paper
• Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer

  2021cites this paper
• Statins as adjuvants in the treatment of ovarian cancer: controversy and misunderstanding.

  2021cites this paper
• Association between statin use and the risk, prognosis of gynecologic cancer: A meta-analysis.

  2021cites this paper
• Do statins play any role in reducing the incidence and mortality of ovarian cancer? A systematic review and meta-analysis

  2020cites this paper
• Systematic review and meta-analysis of studies assessing the relationship between statin use and risk of ovarian cancer

  2020cites this paper
• An Overview of Candidate Therapeutic Target Genes in Ovarian Cancer

  2020cites this paper
• Beyond lipid-lowering: role of statins in endometrial cancer

  2020cites this paper
• The role of metformin and statins in ovarian and breast cancer in women with type 2 diabetes

  2019cites this paper
• Statin use and the risk of ovarian and endometrial cancers: a meta-analysis

  2019cites this paper
• Expression of NR1H3 in endometrial carcinoma and its effect on the proliferation of Ishikawa cells in vitro

  2019cites this paper
• ’ s response to reviews Title : Statin use and the risk of ovarian and endometrial cancers : A meta-analysis

  2019cites this paper
• Statin Use Prior to Diagnosis Predicts High Risk Features in Early Stage Endometrioid Endometrial Cancer

  2018cites this paper
• The role of metformin and statins in the incidence of epithelial ovarian cancer in type 2 diabetes: a cohort and nested case–control study

  2018cites this paper
• An analysis of the association between statin use and risk of endometrial and ovarian cancers in the Women's Health Initiative.

  2018cites this paper
• Statin therapy and association with ovarian cancer risk in the New England Case Control (NEC) study

  2018influential citation
• Activation of LXRɑ/β by cholesterol in malignant ascites promotes chemoresistance in ovarian cancer

  2018cites this paper
• Statin use and risk of endometrial cancer: a nationwide registry‐based case–control study

  2017cites this paper
• Statin use and endometrial cancer risk: a meta-analysis

  2017cites this paper
• Protective Effects of Statins in Cancer: Should They Be Prescribed for High-Risk Patients?

  2016cites this paper
• Impact of statins on risk and survival of ovarian cancer

  2015influential citation
• Endometrial Cancer and The Role of Statins

  2015cites this paper
• The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer

  2015cites this paper
• Drugs with potential chemopreventive properties in relation to epithelial ovarian cancer--a nationwide case-control study.

  2015cites this paper
• Statin use and risk for ovarian cancer: a Danish nationwide case–control study

  2014cites this paper
• The effect of bisphosphonates on the risk of endometrial and ovarian malignancies.

  2014cites this paper
• Effect of statin on risk of gynecologic cancers: a meta-analysis of observational studies and randomized controlled trials.

  2014influential citation
• The effect of statins on risk and survival of gynecological malignancies.

  2013cites this paper
• Long-term Statin Use and Risk of Breast Cancer—Letter

  2013cites this paper
• New Players for Advanced Prostate Cancer and the Rationalisation of Insulin-Sensitising Medication

  2013cites this paper
• Beyond aspirin—cancer prevention with statins, metformin and bisphosphonates

  2013cites this paper
• Health Maintenance Organizations/Health Plans

  2012cites this paper
• Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: results of a United States case-control study.

  2011cites this paper
• The role of insulin and IGF2 signalling on metabolic pathways in prostate cancer progression

  2011cites this paper
• Antitumor effects of atorvastatin in the chemoprevention of rat mammary carcinogenesis

  2011cites this paper
• Simvastatin reduces tumor cell adhesion to human peritoneal mesothelial cells by decreased expression of VCAM-1 and β1 integrin.

  2011cites this paper
• Statin use and cancer risk: a comprehensive review

  2010cites this paper
• Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort.

  2010cites this paper
• Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells.

  2010cites this paper
• Incidence of cancer and statin usage—Record linkage study

  2010cites this paper
• Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer

  2010cites this paper
• Current world literature.

  2010cites this paper
• Authors’ reply to: Statin therapy as the fundamental therapy for cardiovascular prevention: be careful

  2009cites this paper
• Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase

  2009cites this paper
• Pharmacoepidemiology and drug safety

  2009cites this paper